Evidence map›Paper›PMID 39436656›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

Complement activation by IgG subclasses is governed by their ability to oligomerize upon antigen binding.

Nikolaus Frischauf, Jürgen Strasser, Ellen G F Borg, Aran F Labrijn, Frank J Beurskens, Johannes Preiner

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Interleukin-23 Inhibitors in Inflammatory Bowel Disease.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nikolaus Frischauf *Medical Engineering, Nano Structuring and Bio-Analytics, University of Applied Sciences Upper Austria, Linz 4020, Austria.
Jürgen Strasser *Medical Engineering, Nano Structuring and Bio-Analytics, University of Applied Sciences Upper Austria, Linz 4020, Austria.ORCID 0000-0002-9722-702X
Ellen G F BorgGenmab, Utrecht 3584 CT, The Netherlands.
Aran F LabrijnGenmab, Utrecht 3584 CT, The Netherlands.ORCID 0000-0001-9239-8439
Frank J BeurskensGenmab, Utrecht 3584 CT, The Netherlands.ORCID 0000-0002-7165-5771
Johannes PreinerMedical Engineering, Nano Structuring and Bio-Analytics, University of Applied Sciences Upper Austria, Linz 4020, Austria.ORCID 0000-0002-6755-6543

Funding

Austrian Science Fund (FWF) 33958Austrian Science Fund (FWF) 34164
6 · The paper itself

Abstract

Complement activation through antibody-antigen complexes is crucial in various pathophysiological processes and utilized in immunotherapies to eliminate infectious agents, regulatory immune cells, or cancer cells. The tertiary structures of the four IgG antibody subclasses are largely comparable, with the most prominent difference being the hinge regions connecting the Fab and Fc domains, providing them with unique structural flexibility. Complement recruitment and activation depend strongly on IgG subclass, which is commonly rationalized by differences in hinge flexibility and the respective affinities for C1, the first component of the classical complement pathway. However, a unifying mechanism of how these different IgG subclass properties combine to modulate C1 activation has not yet been proposed. We here demonstrate that complement activation is determined by their varying ability to form IgG oligomers on antigenic surfaces large enough to multivalently bind and activate C1. We directly visualize the resulting IgG oligomer structures and characterize their distribution by means of high-speed atomic force microscopy, quantify their complement recruitment efficiency from quartz crystal microbalance experiments, and characterize their ability to activate complement on tumor cell lines as well as in vesicle-based complement lysis assays. We present a mechanistic model of the multivalent interactions that govern C1 binding to IgG oligomers and use it to extract kinetic rate constants from real-time interaction data from which we further calculate equilibrium dissociation constants. Together, we provide a comprehensive view on the parameters that govern complement activation by the different IgG subclasses, which may inform the design of future antibody therapies.

Indexed as

Complement ActivationImmunoglobulin GAntigen-Antibody ComplexAntigensCell Line, TumorComplement C1HumansMicroscopy, Atomic ForceProtein BindingProtein MultimerizationAntigen-Antibody ComplexAntigensComplement C1Immunoglobulin GC1classical complement pathwayFc–Fc interactionsIgG oligomerizationIgG subclasses

Identifiers

PMID39436656
PMCPMC11536094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.